

# PRESS RELEASE



## Hansa Biopharma to participate in three upcoming investor conferences

Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs' Biotech Symposium in London, Morgan Stanley's Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in London.

**Lund, Sweden August 21, 2019.** Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences:

- The Goldman Sachs Ninth Annual Biotech Symposium in London on Friday, September 6, 2019.
- The Morgan Stanley 17<sup>th</sup> Annual Global Healthcare Conference in New York City, NY Tuesday, September 10, 2019, with a presentation at 1:30 PM EST/ 19:30 CET on the same day.
- The Bank of America Merrill Lynch Global Healthcare Conference 2019 in London from Thursday, September 19, 2019 to Friday, September 20, 2019, with a presentation at 14:45 CET on Friday September 20.

A live webcast of the Morgan Stanley presentation will be available on the Events & Webcast page of the Company's website, [www.hansabiopharma.com](http://www.hansabiopharma.com). A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

The information was submitted for publication, through the contact person set out below at 08:00 (CET) on August 21, 2019.

#### Contact information

Klaus Sindahl  
Head of Investor Relations  
Hansa Biopharma  
M: +46 (0) 709-298 269  
E: [klaus.sindahl@hansabiopharma.com](mailto:klaus.sindahl@hansabiopharma.com)

Rolf Gulliksen  
Head of Corporate Communications  
Hansa Biopharma  
M: +46 (0) 733-328 634  
E: [rolf.gulliksen@hansabiopharma.com](mailto:rolf.gulliksen@hansabiopharma.com)

#### About Hansa Biopharma

Hansa Biopharma is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.

Hansa Biopharma  
Scheelevägen 22  
SE- 223 63 Lund, Sweden  
Phone: +46 46 16 56 70  
[www.hansabiopharma.com](http://www.hansabiopharma.com)

Nasdaq OMX Stockholm  
Ticker: HSNA  
ISIN: SE 0002148817